NCT04244435

Neuroaxial Prophylaxis for CABG

Consequences of Using Thoracic Epidural Analgesia for Coronary Artery Bypass Grafting

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Volgograd State Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Investigators plan to study the effect of thoracic epidural analgesia on postoperative parameters (complication rate, duration of hospitalization, mortality, etc.) of coronary artery bypass grafting.

Detailed description

Investigators plan to conduct a comparative analysis of early postoperative complications of coronary artery bypass grafting with and without cardiopulmonary bypass in patients with independent risk factors for the development of postoperative complications (advanced age, diabetes mellitus, chronic kidney disease, obesity, chronic obstructive pulmonary disease) with various types of anesthesiology benefits (general anesthesia and thoracic epidural analgesia versus general anesthesia and opioids). Investigators predict a decrease in the risk of developing cardiac, respiratory, infectious and renal complications, a reduction in the duration of intensive care, inpatient treatment and mortality.

Conditions

• Coronary Artery Occlusion

Interventions

Type	Name	Description
PROCEDURE	CABG	coronary artery bypass grafting with and without cardiopulmonary bypass
DRUG	thoracic epidural analgesia	thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
DRUG	analgesia of opioids	Opioids will be used for perioperative analgesia

Timeline

• Start date: 2020-02-01
• Primary completion: 2020-12-31
• Completion: 2022-01-31
• First posted: 2020-01-28
• Last updated: 2021-09-21

Locations

1 site across 1 country: Russia